Stockreport

Zentalis Pharmaceuticals Reports Full Year 2025 Financial Results and Operational Updates

Zentalis Pharmaceuticals, Inc. - common stock  (ZNTL) 
PDF On track for DENALI Part 2a dose confirmation in 1H 2026DENALI Part 2 trial topline readout expected by year end 2026; potential to support accelerated approvalOn track [Read more]